Clinical · Molecular biology · Bioinfo & AI
Biallelic loss of RB1 in hepatocellular carcinoma as synthetic lethal target for artificial intelligence-guided therapy
This study characterized biallelic inactivation of the RB1 tumor suppressor gene (RB1-Bi) in hepatocellular carcinoma (HCC), finding it in 14.6% of patients and associating it with significantly reduced overall survival. A deep learning model (FR-MIL) was developed to accurately predict RB1-Bi status from routine histopathology slides. High-throughput drug screenings revealed that RB1-Bi HCC cells are particularly sensitive to inhibitors targeting mitotic regulators and PARP inhibitors. These synthetic lethal interactions were validated in vitro and in vivo, suggesting RB1-Bi is an actionable biomarker for precision medicine in HCC.